Laura Papetti

Dr. Laura Papetti

Bambino Gesù Children Hospital, Rome
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
MNMargherita Nosadini
Margherita Nosadini
TGTiziana Granata
Tiziana Granata
SMSara Matricardi
Sara Matricardi
EFElena Freri
Elena Freri
FRFrancesca Ragona
Francesca Ragona
IEItalian Working Group on Paediatric Anti‐N‐methyl‐D‐aspartate Receptor Encephalitis
Italian Working Group on Paediatric Anti‐N‐methyl‐D‐aspartate Receptor Encephalitis

8 December 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MGM. Gastaldi
M. Gastaldi
SMS. Mariotto
S. Mariotto
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
RIR. Iorio
R. Iorio
MZM. Zoccarato
M. Zoccarato
DFD. Franciotta
D. Franciotta

15 February 2019 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
LPLaura Papetti
Laura Papetti
ISIrene Salfa
Irene Salfa
BBBarbara Battan
Barbara Battan
RMRomina Moavero
Romina Moavero
CTCristiano Termine
Cristiano Termine
Massimiliano ValerianiMassimiliano Valeriani
Massimiliano Valeriani
Introduction: Chronic headaches are not a rare condition in children and adolescents with negative effects on their quality of life. Our aims were to investigate the clinical features of chronic headache and usefulness of the International Classification of Headache Disorders 3rd edition (ICHD 3) criteria for the diagnosis in a cohort of pediatric patients. Methods: We retrospectively reviewed the charts of patients attending the Headache Center of Bambino Gesù Children and Insubria University Hospital during the 2010–2016 time interval. Statistical analysis was conducted to study possible correlations between: (a) chronic primary headache (CPH) and demographic data (age and sex), (b) CPH and headache qualitative features, (c) CPH and risk of medication overuse headache (MOH), and (d) CPH and response to prophylactic therapies. Moreover, we compared the diagnosis obtained by ICHD 3 vs. ICHD 2 criteria Results: We included 377 patients with CPH (66.4% females, 33.6% males, under 18 years of age). CPH was less frequent under 6 years of age (0.8%; p < 0.05) and there was no correlation between age/sex and different CPH types. The risk to develop MOH was higher after 15 years of age (p < 0.05). When we compared the diagnosis obtained by ICHD 2 and ICHD 3 criteria we found a significant difference for the undefined diagnosis (2.6% vs. 7.9%; p < 0.05), while the diagnosis of probable chronic migraine was only possible by using the ICHD2 criteria (11.9% of patients; p < 0.05). The main criterion which was not satisfied for a definitive diagnosis was the duration of the attacks less than 2 h (70% of patients younger than 6 years; p < 0.005). Amitriptyline and topiramate were the most effective drugs (p < 0.05), although no significant difference was found between them (p > 0.05). Conclusion: The ICHD 3 criteria show limitations when applied to children under 6 years of age. The risk of developing MOH increases with age. Although our “real word” study shows that amitriptyline and topiramate are the most effective drugs regardless of the CPH type, the lack of placebo-controlled data and the limited follow-up results did not allow us to conclude about the drug efficacy.

Verified
Journal Article
Open access
PDF file
GCGiulia Ceglie
Giulia Ceglie
LPLaura Papetti
Laura Papetti
Massimiliano ValerianiMassimiliano Valeriani
Massimiliano Valeriani
PMPietro Merli
Pietro Merli
Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory disorders of the central nervous system (CNS). Understanding of the molecular basis of these diseases in the last decades has led to an important improvement in the treatment of this disease, in particular, to the use of immunotherapeutic approaches, such as monoclonal antibodies and Hematopoietic Stem Cell Transplantation (HSCT). The aim of this review is to summarize the pathogenesis, biological basis and new treatment options of these disorders, with a particular focus on HSCT applications. Different HSCT strategies are being explored in NMOSD, both autologous and allogeneic HSCT, with the new emergence of therapeutic effects such as an induction of tolerance to auto-antigens and graft versus autoimmunity effects that can be exploited to hopefully treat a disease that still has prognosis.

18 July 2016 in Cephalalgia
Verified
Journal Article
Open access
RTRoberto Torriero
Roberto Torriero
ACAlessandro Capuano
Alessandro Capuano
RMRosanna Mariani
Rosanna Mariani
RFRoberto Frusciante
Roberto Frusciante
STSamuela Tarantino
Samuela Tarantino
Massimiliano ValerianiMassimiliano Valeriani
Massimiliano Valeriani
Background: Criteria defined by the International headache Society are commonly used for the diagnosis of the different headache types in both adults and children. However, some authors have stressed some limits of these criteria when applied to preschool age. Objective: Our study aimed to describe the characteristics of primary headaches in children younger than 6 years and investigate how often the International Classification of Headache Disorders (ICHD) criteria allow a definitive diagnosis. Methods: This retrospective study analysed the clinical feature of 368 children younger than 6 years with primary headache. Results: We found that in our patients the percentage of undefined diagnosis was high when either the ICHD-II or the ICHD-III criteria were used. More than 70% of our children showed a duration of their attacks shorter than 1 hour. The absence of photophobia/phonophobia and nausea/vomiting significantly correlate with tension-type headache (TTH) and probable TTH. The number of first-degree relatives with migraine was positively correlated to the diagnosis of migraine in the patients ( p  < 0.001). Conclusions: Our study showed that the ICHD-III criteria are difficult to use in children younger than 6 years. The problem is not solved by the reduction of the lowest duration limit for the diagnosis of migraine to 1 hour, as was done in the ICHD-II.

6 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
LPLaura Papetti
Laura Papetti
RMRomina Moavero
Romina Moavero
MFMichela A. N. Ferilli
Michela A. N. Ferilli
GSGiorgia Sforza
Giorgia Sforza
STSamuela Tarantino
Samuela Tarantino
Massimiliano ValerianiMassimiliano Valeriani
Massimiliano Valeriani
The link between migraine and nutrition can be explored from several points of view. Lifestyle and, in particular, aspects of nutrition can have a significant impact on the course of pediatric migraine. In addition, some dietary treatments, such as the ketogenic diet, and some active ingredients present in foods (nutraceuticals) may have a therapeutic effect on migraine. A diet that can control weight gain and obesity has beneficial effects on migraine severity. On the other hand, when we talk about the link between nutrition and headaches, it is also necessary to point out that some public information is actually fake news that has no scientific basis. The purpose of this review is to provide an update on the salient points linking pediatric migraine to nutritional principles, focusing on the relationship between weight and headaches, the therapeutic effect of food for medical purposes, the ketogenic diet as a migraine treatment, and the relationship between migraine and dietary habits.